Bellevue Group Ag Uni Qure N.V. Transaction History

Bellevue Group Ag

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 12, 2021	SELL	$29.97 - $37.17 $1.03 Million - $1.28 Million	-34,500 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$45.06 - $67.74 $135,180 - $203,219	3,000 Added 9.52%	34,500 $1.56 Million
Q1 2020 May 14, 2020	BUY	$40.01 - $73.97 $104,026 - $192,322	2,600 Added 9.0%	31,500 $1.5 Million
Q4 2019 Feb 14, 2020	SELL	$37.13 - $74.62 $74,260 - $149,240	-2,000 Reduced 6.47%	28,900 $2.07 Million
Q3 2019 Nov 14, 2019	BUY	$39.36 - $76.8 $129,888 - $253,440	3,300 Added 11.96%	30,900 $1.22 Million
Q2 2019 Aug 14, 2019	SELL	$52.76 - $82.19 $564,532 - $879,433	-10,700 Reduced 27.94%	27,600 $2.16 Million
Q1 2019 May 15, 2019	BUY	$27.39 - $68.41 $775,137 - $1.94 Million	28,300 Added 283.0%	38,300 $2.29 Million
Q4 2018 Feb 12, 2019	SELL	$22.8 - $33.93 $225,720 - $335,907	-9,900 Reduced 49.75%	10,000 $288,000
Q3 2018 Nov 13, 2018	SELL	$29.75 - $43.08 $8,925 - $12,924	-300 Reduced 1.49%	19,900 $724,000
Q2 2018 Aug 07, 2018	BUY	$21.96 - $39.94 $443,592 - $806,788	20,200 New	20,200 $764,000

153

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $270M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Bellevue Group Ag, based on Form 13F filings with the SEC.

Stay updated on Bellevue Group Ag with notifications on news.